Cross Talk Pathways between Coagulation and Inflammation

Circulation Research

Volumn 118, Issue 9, 2016, Pages 1392-1408

  Foley, Jonathan H ^a,b   Conway, Edward M ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

complement; contact activation; endothelial; monocyte; platelet thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 7A; CD40 LIGAND; COMPLEMENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL PROTEIN C RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VORAPAXAR; SERINE PROTEINASE;

ALTERNATIVE RNA SPLICING; ARTERY THROMBOSIS; BLOOD CLOTTING; CYTOKINE PRODUCTION; EXTRACELLULAR TRAP; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; KALLIKREIN KININ SYSTEM; MEMBRANE MICROPARTICLE; MOLECULAR INTERACTION; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; TISSUE INJURY; ANIMAL; BLOOD; METABOLISM; THROMBOSIS;

ANIMALS; EXTRACELLULAR TRAPS; FIBRINOLYSIS; HUMANS; IMMUNITY, INNATE; PROTEIN C; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84968624624     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.306853     Document Type: Review

References (205)

1. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Müller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383:73-75. doi: 10.1038/383073a0.
2. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood. 1996;88:1583-1587.
3. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87:6934-6938.
4. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol. 2006;26:456-461. doi: 10.1161/01.ATV.0000202656.53964.04.
5. Osterud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis. 1995;6(suppl 1):S20-S25.
6. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(suppl 1):S70-S73. doi: 10.1016/j. thromres.2010.01.042.
7. Morrissey JH. Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma. Blood Coagul Fibrinolysis. 1995;6(suppl 1):S14-S19.
8. Danckwardt S, Hentze MW, Kulozik AE. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl). 2013;91:1257-1271. doi: 10.1007/s00109-013-1074-5.
9. Camerer E, Huang W, Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97:5255-5260.
10. Demetz G, Seitz I, Stein A, Steppich B, Groha P, Brandl R, Schömig A, Ott I. Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis. 2010;212:466-471. doi: 10.1016/j.atherosclerosis.2010.07.017.
11. Langer F, Spath B, Fischer C, Stolz M, Ayuk FA, Kröger N, Bokemeyer C, Ruf W. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood. 2013;121:2324-2335. doi: 10.1182/blood-2012-10-460493.
12. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5. doi: 10.1189/jlb.0306164.
13. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev. 2009;227:248-263. doi: 10.1111/j.1600-065X.2008.00733.x.
14. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13:460-469. doi: 10.1016/j.molmed.2007.09.002.
15. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004;103:1342-1347. doi: 10.1182/blood-2003-09-3051.
16. Sharma L, Melis E, Hickey MJ, Clyne CD, Erlich J, Khachigian LM, Davenport P, Morand E, Carmeliet P, Tipping PG. The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia. Am J Pathol. 2004;165:331-340. doi: 10.1016/S0002-9440(10)63300-7.
17. Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, van der Voort D, Hamulyák K, Petersen LC, Spronk HM, ten Cate H. Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. J Thromb Haemost. 2009;7:290-298. doi: 10.1111/j.1538-7836.2008.03232.x.
18. Ruf W, Samad F. Tissue factor pathways linking obesity and inflammation. Hamostaseologie. 2015;35:279-283. doi: 10.5482/HAMO-14-11-0068.
19. Bode MF, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2015;35:37-46. doi: 10.5482/HAMO-14-09-0042.
20. van den Boogaard FE, van 't Veer C, Roelofs JJ, Meijers JC, Schultz MJ, Broze GJ Jr, van der Poll T. Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia. Thromb Haemost. 2015;114:115-122. doi: 10.1160/TH14-12-1053.
21. Maroney SA, Ellery PE, Mast AE. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res. 2010;125(suppl 1):S52-S56. doi: 10.1016/j.thromres.2010.01.038.
22. Ellery PE, Adams MJ. Tissue factor pathway inhibitor: then and now. Semin Thromb Hemost. 2014;40:881-886. doi: 10.1055/s-0034-1395153.
23. Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2860. doi: 10.1172/JCI116529.
24. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247. doi: 10.1001/jama.290.2.238.
25. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311-2315.
26. Cimmino G, Ciccarelli G, Golino P. Role of tissue factor in the coagulation network. Semin Thromb Hemost. 2015;41:708-717. doi: 10.1055/s-0035-1564045.
27. Camera M, Brambilla M, Toschi V, Tremoli E. Tissue factor expression on platelets is a dynamic event. Blood. 2010;116:5076-5077. doi: 10.1182/blood-2010-09-307306.
28. Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. Blood. 2010;116:854-855. doi: 10.1182/blood-2010-05-285627.
29. Del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factorbearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604-1611. doi: 10.1182/blood-2004-03-1095.
30. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003;9:458-462. doi: 10.1038/nm841.
31. Xue M, Sun Z, Shao M, et al. Diagnostic and prognostic utility of tissue factor for severe sepsis and sepsis-induced acute lung injury. J Transl Med. 2015;13:172. doi: 10.1186/s12967-015-0518-9.
32. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264. doi: 10.1038/35025229.
33. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
34. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690-694. doi: 10.1038/29325.
35. Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem. 1994;269:27719-27726.
36. Woolkalis MJ, DeMelfi TM Jr, Blanchard N, Hoxie JA, Brass LF. Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem. 1995;270:9868-9875.
37. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887. doi: 10.1172/JCI6042.
38. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101:880-886.
39. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594. doi: 10.1038/35393.
40. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207. doi: 10.1038/35051599.
41. Drake WT, Lopes NN, Fenton JW II, Issekutz AC. Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. Lab Invest. 1992;67:617-627.
42. Sower LE, Froelich CJ, Carney DH, Fenton JW II, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol. 1995;155:895-901.
43. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209:819-835. doi: 10.1084/jem.20112322.
44. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002;99:1053-1059.
45. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
46. Morrow DA, Braunwald E, Bonaca MP, et al; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-1413. doi: 10.1056/NEJMoa1200933.
47. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem. 1976;251:355-363.
48. Esmon CT, Stenflo J, Suttie JW. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem. 1976;251:3052-3056.
49. Esmon CT, Esmon NL, Harris KW. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982;257:859-864.
50. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A. 1996;93:10212-10216.
51. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
52. Wu C, Dwivedi DJ, Pepler L, Lysov Z, Waye J, Julian J, Desch K, Ginsburg D, Weitz JI, Kearon C, Liaw PC. Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism. Arterioscler Thromb Vasc Biol. 2013;33:2674-2681. doi: 10.1161/ATVBAHA.113.302137.
53. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882. doi: 10.1126/science.1071699.
54. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol. 2000;110:130-134.
55. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost. 2005;3:1351-1359. doi: 10.1111/j.1538-7836.2005.01385.x.
56. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood. 2015;125:2898-2907. doi: 10.1182/blood-2015-02-355974.
57. Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood. 2014;124:1553-1562. doi: 10.1182/blood-2014-05-578328.
58. Esmon CT. Structure and functions of the endothelial cell protein C receptor. Crit Care Med. 2004;32:S298-S301.
59. Kerschen E, Hernandez I, Zogg M, Jia S, Hessner MJ, Fernandez JA, Griffin JH, Huettner CS, Castellino FJ, Weiler H. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010;120:3167-3178. doi: 10.1172/JCI42629.
60. Disse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon CT, Teyton L, Petersen LC, Ruf W. The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through proteaseactivated receptors. J Biol Chem. 2011;286:5756-5767. doi: 10.1074/jbc. M110.201228.
61. Liang HP, Kerschen EJ, Basu S, Hernandez I, Zogg M, Jia S, Hessner MJ, Toso R, Rezaie AR, Fernández JA, Camire RM, Ruf W, Griffin JH, Weiler H. Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood. 2015;126:2415-2423. doi: 10.1182/blood-2015-05-644401.
62. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102:3085-3092. doi: 10.1182/blood-2003-06-1789.
63. Morser J. Thrombomodulin links coagulation to inflammation and immunity. Curr Drug Targets. 2012;13:421-431.
64. Zoja C, Locatelli M, Pagani C, Corna D, Zanchi C, Isermann B, Remuzzi G, Conway EM, Noris M. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J Immunol. 2012;189:3661-3668. doi: 10.4049/jimmunol.1102118.
65. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolyticuremic syndrome. N Engl J Med. 2009;361:345-357. doi: 10.1056/NEJMoa0810739.
66. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol. 2012;34:107-125. doi: 10.1007/s00281-011-0282-8.
67. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013;304:H1585-H1597. doi: 10.1152/ajpheart.00096.2013.
68. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
69. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-397. doi: 10.1038/41131.
70. Sabroe I, Parker LC, Dower SK, Whyte MK. The role of TLR activation in inflammation. J Pathol. 2008;214:126-135. doi: 10.1002/path.2264.
71. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science. 2004;304:1014-1018. doi: 10.1126/science.1096158.
72. Leonard JN, Ghirlando R, Askins J, Bell JK, Margulies DH, Davies DR, Segal DM. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci U S A. 2008;105:258-263. doi: 10.1073/pnas.0710779105.
73. Núñez Miguel R, Wong J, Westoll JF, Brooks HJ, O'Neill LA, Gay NJ, Bryant CE, Monie TP. A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS One. 2007;2:e788. doi: 10.1371/journal. pone.0000788.
74. Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000Prime Rep. 2014;6:97. doi: 10.12703/P6-97.
75. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640-643. doi: 10.1126/science.1087262.
76. Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24-32. doi: 10.1016/j.smim.2006.12.004.
77. Laplante P, Fuentes R, Salem D, Subang R, Gillis MA, Hachem A, Farhat N, Qureshi ST, Fletcher CA, Roubey RA, Merhi Y, Thorin É, Levine JS, Mackman N, Rauch J. Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4. Lupus. 2016;25:162-176. doi: 10.1177/0961203315603146.
78. Stark RJ, Aghakasiri N, Rumbaut RE. Platelet-derived Toll-like receptor 4 (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxemia. PLoS One. 2012;7:e41254. doi: 10.1371/journal.pone.0041254.
79. Ren M, Li R, Luo M, Chen N, Deng X, Yan K, Zeng M, Wu J. Endothelial cells but not platelets are the major source of Toll-like receptor 4 in the arterial thrombosis and tissue factor expression in mice. Am J Physiol Regul Integr Comp Physiol. 2014;307:R901-R907. doi: 10.1152/ajpregu.00324.2014.
80. Yang X, Li L, Liu J, Lv B, Chen F. Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-kappaB and AP-1. Thromb Res. 2016;137:211-218. doi: 10.1016/j. thromres.2015.10.012.
81. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118:1952-1961. doi: 10.1182/blood-2011-03-343061.
82. El Kebir D, Damlaj A, Makhezer N, Filep JG. Toll-like receptor 9 signaling regulates tissue factor and tissue factor pathway inhibitor expression in human endothelial cells and coagulation in mice. Crit Care Med. 2015;43:e179-e189. doi: 10.1097/CCM.0000000000001005.
83. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology. 2010;215:1-11. doi: 10.1016/j. imbio.2009.08.006.
84. Gál P, Barna L, Kocsis A, Závodszky P. Serine proteases of the classical and lectin pathways: similarities and differences. Immunobiology. 2007;212:267-277. doi: 10.1016/j.imbio.2006.11.002.
85. Pangburn MK, Müller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol. 1984;7:163-192.
86. Podack ER, Biesecker G, Kolb WP, Müller-Eberhard HJ. The C5b-6 complex: reaction with C7, C8, C9. J Immunol. 1978;121:484-490.
87. Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002;169:2102-2110.
88. Sayah S, Ischenko AM, Zhakhov A, Bonnard AS, Fontaine M. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression. J Neurochem. 1999;72:2426-2436.
89. Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology. 2015. doi: 10.1016/j.imbio.2015.04.006.
90. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794-4802.
91. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147-1155. doi: 10.1172/JCI117430.
92. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;68:875-880.
93. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985-4996; quiz 5105. doi: 10.1182/blood-2012-09-311381.
94. Johnstone RM. Exosomes biological significance: a concise review. Blood Cells Mol Dis. 2006;36:315-321. doi: 10.1016/j.bcmd.2005.12.001.
95. Huber HJ, Holvoet P. Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis. Curr Opin Lipidol. 2015;26:412-419. doi: 10.1097/MOL.0000000000000214.
96. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109:175-180.
97. Christersson C, Lindahl B, Siegbahn A. The composition and daily variation of microparticles in whole blood in stable coronary artery disease. Scand J Clin Lab Invest. 2016;76:25-32. doi: 10.3109/00365513.2015.1086928.
98. Suades R, Padró T, Badimon L. The role of blood-borne microparticles in inflammation and hemostasis. Semin Thromb Hemost. 2015;41:590-606. doi: 10.1055/s-0035-1556591.
99. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis. 2006;36:182-187. doi: 10.1016/j.bcmd.2005.12.019.
100. Shai E, Rosa I, Parguiña AF, Motahedeh S, Varon D, García Á. Comparative analysis of platelet-derived microparticles reveals differences in their amount and proteome depending on the platelet stimulus. J Proteomics. 2012;76(spec No):287-296. doi: 10.1016/j. jprot.2012.02.030.
101. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654-659. doi: 10.1038/ncb1596.
102. Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E, Klement GL, Sola-Visner M, Italiano JE Jr. Megakaryocytederived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009;113:1112-1121. doi: 10.1182/blood-2008-06-163832.
103. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest. 2004;34:392-401. doi: 10.1111/j.1365-2362.2004.01355.x.
104. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. J Immunol. 2015;194:5579-5587. doi: 10.4049/jimmunol.1500259.
105. Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A. 2016;89:111-122. doi: 10.1002/cyto.a.22647.
106. Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipiddependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost. 2010;103:1044-1052. doi: 10.1160/TH09-09-0644.
107. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, Freyssinet JM. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol. 2006;26:2594-2604. doi: 10.1161/01.ATV.0000246775.14471.26.
108. Lin HC, Chang HW, Hsiao SH, Chou ML, Seghatchian J, Burnouf T. Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. Transfus Apher Sci. 2015;53:246-252. doi: 10.1016/j. transci.2015.10.002.
109. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687-1693. doi: 10.1161/ATVBAHA.107.141911.
110. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyteversus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol. 2005;78:1318-1326. doi: 10.1189/jlb.0405193.
111. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renné T, ten Cate H, Spronk HM. Platelet-and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012;10:1355-1362. doi: 10.1111/j.1538-7836.2012.04758.x.
112. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232-240. doi: 10.1056/NEJMoa1405760.
113. Gruber A. The role of the contact pathway in thrombus propagation. Thromb Res. 2014;133(suppl 1):S45-S47. doi: 10.1016/j. thromres.2014.03.019.
114. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endotheliumderived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol. 2004;286:H1910-H1915. doi: 10.1152/ajpheart.01172.2003.
115. Densmore JC, Signorino PR, Ou J, Hatoum OA, Rowe JJ, Shi Y, Kaul S, Jones DW, Sabina RE, Pritchard KA Jr, Guice KS, Oldham KT. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock. 2006;26:464-471. doi: 10.1097/01. shk.0000228791.10550.36.
116. Pitanga TN, de Aragão França L, Rocha VC, Meirelles T, Borges VM, Gonçalves MS, Pontes-de-Carvalho LC, Noronha-Dutra AA, dos-Santos WL. Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells. BMC Cell Biol. 2014;15:21. doi: 10.1186/1471-2121-15-21.
117. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ. Plateletderived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol. 2002;30:450-459.
118. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol. 2004;124:376-384.
119. Arderiu G, Peña E, Badimon L. Angiogenic microvascular endothelial cells release microparticles rich in tissue factor that promotes postischemic collateral vessel formation. Arterioscler Thromb Vasc Biol. 2015;35:348-357. doi: 10.1161/ATVBAHA.114.303927.
120. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res. 2005;67:30-38. doi: 10.1016/j. cardiores.2005.04.007.
121. Boudreau LH, Duchez AC, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124:2173-2183. doi: 10.1182/blood-2014-05-573543.
122. Pluskota E, Woody NM, Szpak D, Ballantyne CM, Soloviev DA, Simon DI, Plow EF. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood. 2008;112:2327-2335. doi: 10.1182/blood-2007-12-127183.
123. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206:1913-1927. doi: 10.1084/jem.20082297.
124. Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, Wagner DD. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost. 2015;13:1310-1319. doi: 10.1111/jth.13002.
125. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP, Ahn YS. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 2005;45:1467-1471. doi: 10.1016/j.jacc.2004.12.075.
126. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005;25:1512-1518. doi: 10.1161/01.ATV.0000170133.43608.37.
127. Mortaza S, Martinez MC, Baron-Menguy C, Burban M, de la Bourdonnaye M, Fizanne L, Pierrot M, Calès P, Henrion D, Andriantsitohaina R, Mercat A, Asfar P, Meziani F. Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. Crit Care Med. 2009;37:2045-2050. doi: 10.1097/CCM.0b013e3181a00629.
128. Nomura S. Microparticle and Atherothrombotic Diseases. J Atheroscler Thromb. 2016;23:1-9. doi: 10.5551/jat.32326.
129. Chi H, Sun L. Neutrophils of Scophthalmus maximus produce extracellular traps that capture bacteria and inhibit bacterial infection. Dev Comp Immunol. 2016;56:7-12. doi: 10.1016/j.dci.2015.11.005.
130. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535. doi: 10.1126/science.1092385.
131. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176:231-241. doi: 10.1083/jcb.200606027.
132. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191:677-691. doi: 10.1083/jcb.201006052.
133. Björnsdottir H, Welin A, Michaëlsson E, Osla V, Berg S, Christenson K, Sundqvist M, Dahlgren C, Karlsson A, Bylund J. Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic Biol Med. 2015;89:1024-1035. doi: 10.1016/j.freeradbiomed.2015.10.398.
134. Borissoff JI, ten Cate H. From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost. 2011;9:1791-1794. doi: 10.1111/j.1538-7836.2011.04425.x.
135. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880-15885. doi: 10.1073/pnas.1005743107.
136. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2014;123:2768-2776. doi: 10.1182/blood-2013-10-463646.
137. Longstaff C, Varjú I, Sótonyi P, Szabó L, Krumrey M, Hoell A, Bóta A, Varga Z, Komorowicz E, Kolev K. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem. 2013;288:6946-6956. doi: 10.1074/jbc.M112.404301.
138. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014;34:1977-1984. doi: 10.1161/ATVBAHA.114.304114.
139. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011;118:3708-3714. doi: 10.1182/blood-2011-01-332676.
140. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost. 2011;9:1795-1803. doi: 10.1111/j.1538-7836.2011.04422.x.
141. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318-1321. doi: 10.1038/nm.2053.
142. Barranco-Medina S, Pozzi N, Vogt AD, Di Cera E. Histone H4 promotes prothrombin autoactivation. J Biol Chem. 2013;288:35749-35757. doi: 10.1074/jbc.M113.509786.
143. Varju I, Longstaff C, Szabo L, Farkas AZ, Varga-Szabo VJ, Tanka-Salamon A, Machovich R, Kolev K. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost. 2015;113:1289-1298. doi: 10.1160/TH14-08-0669.
144. Gould TJ, Vu TT, Stafford AR, Dwivedi DJ, Kim PY, Fox-Robichaud AE, Weitz JI, Liaw PC. Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis. Arterioscler Thromb Vasc Biol. 2015;35:2544-2553. doi: 10.1161/ATVBAHA.115.306035.
145. Glaser C, Morser J, Clarke J, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews W, Light D. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for moduclation of coagulation. J Clin Invest. 1992;90:2565-2573.
146. Higuchi DA, Wun TC, Likert KM, Broze GJ Jr. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood. 1992;79:1712-1719.
147. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10:136-144. doi: 10.1111/j.1538-7836.2011.04544.x.
148. Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, Gallant M, Hu J, Wang Y, Wagner DD. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013;110:8674-8679. doi: 10.1073/pnas.1301059110.
149. Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Nunez-Alvarez C, Hernandez-Ramirez D, Bockenstedt PL, Liaw PC, Cabral AR, Knight JS. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67:2990-3003. doi: 10.1002/art.39247.
150. Riegger J, Byrne RA, Joner M, et al; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort PRESTIGE Investigators. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium [published online ahead of print August 30, 2015]. Eur Heart J. doi: http://dx.doi.org/10.1093/eurheartj/ehv419. http://eurheartj.oxfordjournals.org/content/early/2015/08/25/eurheartj.ehv419.
151. Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S, Tsironidou V, Giatromanolaki A, Skendros P, Konstantinides S, Ritis K. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J. 2015;36:1405-1414. doi: 10.1093/eurheartj/ehv007.
152. Savchenko AS, Martinod K, Seidman MA, Wong SL, Borissoff JI, Piazza G, Libby P, Goldhaber SZ, Mitchell RN, Wagner DD. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost. 2014;12:860-870. doi: 10.1111/jth.12571.
153. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost. 1999;82:259-270.
154. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001;86:346-355.
155. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest. 1984;74:1988-1995. doi: 10.1172/JCI111620.
156. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129:307-321. doi: 10.1111/j.1365-2141.2005.05444.x.
157. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Thromb Res. 1983;29:407-417.
158. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
159. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost. 2003;89:610-621. doi: 10.1267/THRO03040610.
160. Plow EF, Doeuvre L, Das R. So many plasminogen receptors: why? J Biomed Biotechnol. 2012;2012:141806. doi: 10.1155/2012/141806.
161. Swisher JF, Khatri U, Feldman GM. Annexin A2 is a soluble mediator of macrophage activation. J Leukoc Biol. 2007;82:1174-1184. doi: 10.1189/jlb.0307154.
162. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry. 1991;30:1682-1691.
163. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439-444. doi: 10.1038/ng1297-439.
164. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998;188:1029-1037.
165. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
166. Carlin SM, Resink TJ, Tamm M, Roth M. Urokinase signal transduction and its role in cell migration. FASEB J. 2005;19:195-202. doi: 10.1096/fj.04-1644com.
167. Vallabhaneni KC, Tkachuk S, Kiyan Y, Shushakova N, Haller H, Dumler I, Eden G. Urokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells. Cardiovasc Res. 2011;90:113-121. doi: 10.1093/cvr/cvq362.
168. Khan MM, Bradford HN, Isordia-Salas I, Liu Y, Wu Y, Espinola RG, Ghebrehiwet B, Colman RW. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler Thromb Vasc Biol. 2006;26:2260-2266. doi: 10.1161/01.ATV.0000240290.70852.c0.
169. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990;111:783-792.
170. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185:5628-5636. doi: 10.4049/jimmunol.0903678.
171. Foley JH, Peterson EA, Lei V, Wan LW, Krisinger MJ, Conway EM. Interplay between fibrinolysis and complement: plasmin cleavage of iC3b modulates immune responses. J Thromb Haemost. 2015;13:610-618. doi: 10.1111/jth.12837.
172. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459-2465.
173. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1:1575-1579.
174. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
175. Wang J, Wang C, Chen N, Shu C, Guo X, He Y, Zhou Y. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 2014;134:1241-1248. doi: 10.1016/j.thromres.2014.09.035.
176. Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost. 2016;14:28-39. doi: 10.1111/jth.13194.
177. Renné T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol. 2012;34:31-41. doi: 10.1007/s00281-011-0288-2.
178. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007;104:6388-6393. doi: 10.1073/pnas.0608647104.
179. Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest. 2008;118:3006-3009. doi: 10.1172/JCI36617.
180. Oschatz C, Maas C, Lecher B, Jansen T, Björkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Müller-Esterl W, Wuillemin WA, Nilsson G, Renné T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity. 2011;34:258-268. doi: 10.1016/j.immuni.2011.02.008.
181. Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renné T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139:1143-1156. doi: 10.1016/j.cell.2009.11.001.
182. Bouma BN, Miles LA, Beretta G, Griffin JH. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry. 1980;19:1151-1160.
183. Citarella F, Wuillemin WA, Lubbers YT, Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol. 1997;99:197-205.
184. Kayashima Y, Smithies O, Kakoki M. The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens. 2012;21:92-96. doi: 10.1097/MNH.0b013e32834d54b1.
185. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431-1435.
186. Dong R, Chen W, Feng W, Xia C, Hu D, Zhang Y, Yang Y, Wang DW, Xu X, Tu L. Exogenous bradykinin inhibits tissue factor induction and deep vein thrombosis via activating the eNOS/phosphoinositide 3-kinase/Akt signaling pathway. Cell Physiol Biochem. 2015;37:1592-1606. doi: 10.1159/000438526.
187. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost. 2006;95:1003-1010. doi: 10.1160/TH06-03-0128.
188. Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost. 2011;37:362-374. doi: 10.1055/s-0031-1276585.
189. Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy. 2015;70:506-513. doi: 10.1111/all.12587.
190. Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology Am Soc Hematol Educ Program. 2014;2014:66-70. doi: 10.1182/asheducation-2014.1.66.
191. Olson NC, Butenas S, Lange LA, Lange EM, Cushman M, Jenny NS, Walston J, Souto JC, Soria JM, Chauhan G, Debette S, Longstreth WT, Seshadri S, Reiner AP, Tracy RP. Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study. J Thromb Haemost. 2015;13:1867-1877. doi: 10.1111/jth.13111.
192. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696-701. doi: 10.1056/NEJM200003093421004.
193. Suri MF, Yamagishi K, Aleksic N, Hannan PJ, Folsom AR. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis. 2010;29:497-502. doi: 10.1159/000297966.
194. Siegerink B, Rosendaal FR, Algra A. Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women. J Thromb Haemost. 2014;12:606-613.
195. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. 2006;108:4045-4051. doi: 10.1182/blood-2005-12-023697.
196. Salomon O, Steinberg DM, Dardik R, Rosenberg N, Zivelin A, Tamarin I, Ravid B, Berliner S, Seligsohn U. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost. 2003;1:658-661.
197. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991;253:909-912.
198. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem. 1991;266:7353-7358.
199. Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A. 1989;86:7667-7671.
200. Wu Y. Contact pathway of coagulation and inflammation. Thromb J. 2015;13:17. doi: 10.1186/s12959-015-0048-y.
201. Stavrou EX, Fang C, Merkulova A, Alhalabi O, Grobe N, Antoniak S, Mackman N, Schmaier AH. Reduced thrombosis in Klkb1-/-mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 2015;125:710-719. doi: 10.1182/blood-2014-01-550285.
202. Shariat-Madar Z, Mahdi F, Warnock M, Homeister JW, Srikanth S, Krijanovski Y, Murphey LJ, Jaffa AA, Schmaier AH. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood. 2006;108:192-199. doi: 10.1182/blood-2006-01-0094.
203. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renné T, Morrissey JH, Gruber A, Gailani D. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014;123:1739-1746. doi: 10.1182/blood-2013-04-499111.
204. Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, Ronquist G, Renné T. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood. 2015;126:1379-1389. doi: 10.1182/blood-2015-01-622811.
205. Kenne E, Nickel KF, Long AT, Fuchs TA, Stavrou EX, Stahl FR, Renné T. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J Intern Med. 2015;278:571-585. doi: 10.1111/joim.12430.